The Basic Building Blocks: Amino Acids and Peptide Bonds

To understand peptides, you need to start one level down, with amino acids. Amino acids are small organic molecules that share a common backbone: a central carbon atom attached to an amino group (NH2), a carboxyl group (COOH), and a variable side chain that gives each amino acid its distinct chemical character. The human body uses 20 standard amino acids, and the specific sequence in which they're arranged determines what a peptide or protein does.

When two amino acids join together, a water molecule is released and a covalent bond forms between the carboxyl group of one amino acid and the amino group of the next. That bond is called a peptide bond, and it's the defining structural feature of every peptide and protein in existence. A chain of two amino acids is a dipeptide. Three is a tripeptide. Chains up to roughly 50 amino acids are generally called peptides; longer chains are proteins, though the boundary isn't perfectly fixed in scientific literature.

The sequence of amino acids in a chain is called its primary structure. Even a small change, swapping one amino acid for another, can dramatically alter how a peptide behaves, which receptor it binds, how quickly enzymes break it down, and whether it can cross a cell membrane. This sensitivity to sequence is part of why researchers find peptides so interesting as research tools.

How Do Peptides Differ from Proteins?

Size is the most obvious difference. Proteins are long polypeptide chains, often hundreds or thousands of amino acids, that fold into precise three-dimensional shapes. That folding, driven by interactions between side chains and the surrounding water environment, is what gives proteins their function. Enzymes, antibodies, and structural proteins like collagen all depend on this folded architecture.

Peptides are short enough that most don't fold into stable, complex structures the way proteins do. Instead, they tend to work through direct binding: a peptide fits into a receptor or enzyme active site and triggers a response. Because they're smaller, peptides are also generally more fragile in the body. Enzymes called proteases can break peptide bonds, so many naturally occurring peptides have very short half-lives in circulation, sometimes just minutes.

Molecular weight is another way scientists distinguish the two. Peptides typically fall below 5,000 daltons (a unit of molecular mass), while proteins are usually above 10,000 daltons. The zone in between is sometimes called the 'peptide-protein borderland,' and molecules in that range, like insulin at roughly 5,800 daltons, are sometimes classified as either depending on context. Insulin is almost always called a protein in clinical settings, even though it's on the smaller end of that spectrum.

Signaling Peptides: The Body's Chemical Messengers

One of the most studied roles for peptides is cell-to-cell communication. Signaling peptides, sometimes called peptide hormones or neuropeptides depending on where they act, are released by one cell and travel to a target cell where they bind a specific receptor and trigger a downstream response. Insulin is a classic example: it's released by beta cells in the pancreas and signals muscle and fat cells to take up glucose from the blood.

Neuropeptides are a large subclass that act in the nervous system. Endorphins, for instance, are endogenous opioid peptides produced in the brain and pituitary gland. They bind opioid receptors and modulate pain perception. Substance P is another neuropeptide, involved in transmitting pain signals and regulating inflammation. The body produces dozens of neuropeptides, each with a specific receptor profile and a specific set of downstream effects.

Growth hormone-releasing hormone (GHRH) is a 44-amino-acid peptide produced in the hypothalamus that signals the pituitary gland to release growth hormone. Researchers have studied synthetic analogs of GHRH for decades, partly because understanding how signaling peptides work at the receptor level can illuminate broader questions about endocrine regulation. The signaling category is broad, and it's the category most relevant to the synthetic research peptides that get attention in fitness and longevity circles.

Structural and Antimicrobial Peptides

Not all peptides are messengers. Some serve structural roles. Collagen, the most abundant protein in the human body, is broken down during digestion into collagen peptides, short fragments that are small enough to be absorbed into the bloodstream. Once absorbed, these fragments may stimulate fibroblasts, the cells that produce connective tissue, though the research on exactly how this works is still developing. A 2019 review in the journal Nutrients examined multiple randomized controlled trials on oral collagen supplementation and skin outcomes, noting modest improvements in skin elasticity and hydration in several studies, while also flagging the need for larger, longer trials.

Antimicrobial peptides (AMPs) are a completely different functional category. These are short peptides, typically 12 to 50 amino acids, that the immune system uses as a first line of defense against bacteria, fungi, and viruses. They work largely by disrupting microbial cell membranes. Defensins and cathelicidins are two well-studied AMP families found in humans. Researchers are interested in AMPs partly because they kill bacteria through a physical mechanism, which makes it harder for bacteria to develop resistance the way they do against conventional antibiotics.

Bioactive peptides are a broader umbrella term covering peptides that have a measurable effect on a biological system. This includes signaling peptides, antimicrobial peptides, and fragments derived from food proteins during digestion. Casein, a protein in milk, releases several bioactive peptides during digestion that have been studied for effects on blood pressure regulation in animal and small human studies. The evidence quality varies widely across this category, and most findings are still at the preclinical stage.

Synthetic Peptides and the Research Context

Synthetic peptides are made in a laboratory, usually through a process called solid-phase peptide synthesis (SPPS), developed by Robert Bruce Merrifield in the 1960s (work for which he received the Nobel Prize in Chemistry in 1984). SPPS builds a peptide chain one amino acid at a time on a solid resin support, allowing chemists to produce peptides of defined sequence with high purity. This technique made it practical to manufacture peptides at scale for both pharmaceutical development and research.

Some synthetic peptides have become approved pharmaceuticals. Semaglutide, the active ingredient in the branded drugs Ozempic and Wegovy, is a synthetic analog of the naturally occurring peptide GLP-1 (glucagon-like peptide-1). The FDA approved Wegovy specifically for chronic weight management in 2021 and Ozempic for type 2 diabetes management. These approvals apply to those specific branded formulations at specific doses, not to semaglutide as a generic research chemical.

Many other synthetic peptides are sold as research chemicals and have not been approved by the FDA or any equivalent regulatory body. These compounds may have preclinical data, meaning studies in cell cultures or animals, and sometimes small or early-phase human studies, but they haven't completed the clinical trial process required for drug approval. The evidence quality for most research peptides sits firmly in the preclinical tier, and readers should keep that distinction in mind when evaluating claims about them.

The peptide research field is genuinely active. PubMed indexes tens of thousands of peptide-related studies, and new compounds enter preclinical pipelines regularly. But preclinical promise doesn't reliably translate to human benefit, and the gap between an interesting animal study and a proven human therapy is wide. Understanding what peptides are at the molecular level is the foundation for reading that research critically.

Frequently asked questions

Are peptides the same thing as proteins?

No, though they're closely related. Both are chains of amino acids linked by peptide bonds, but peptides are shorter, typically under 50 amino acids, while proteins are longer chains that fold into complex three-dimensional structures. Proteins like enzymes and antibodies depend on that folded shape to function. Most peptides are too short to fold in the same way and instead work by binding directly to receptors or other molecules. The boundary between the two isn't perfectly fixed, and some molecules, like insulin, sit near the border and get classified differently depending on context.

Does the body make its own peptides, or are they only synthetic?

The body produces thousands of peptides naturally. Hormones like insulin and glucagon are peptides. Neuropeptides like endorphins and substance P are produced in the nervous system. Antimicrobial peptides like defensins are part of the innate immune system. Bioactive peptides are also released from food proteins during normal digestion. Synthetic peptides are laboratory-made versions, sometimes identical to naturally occurring ones and sometimes modified to change how they behave, how long they last in the body, or how strongly they bind a receptor.

Why do so many peptides have to be injected rather than taken orally?

Peptides are chains of amino acids, and the digestive system is designed to break amino acid chains apart. Enzymes in the stomach and small intestine, called proteases, cleave peptide bonds efficiently. Most peptides taken orally are broken down into individual amino acids or small fragments before they can reach the bloodstream intact and in a form that would bind their target receptor. Injection bypasses the digestive tract entirely, delivering the peptide directly into tissue or circulation. Some peptides have been formulated for oral delivery by modifying their structure or encapsulating them to resist digestion, but this remains an active area of pharmaceutical research rather than a solved problem.

Sources

  1. Fosgerau & Hoffmann, 2015, Drug Discovery Today, peptide therapeutics overview Covers peptide drug development and structural characteristics
  2. Hancock & Sahl, 2006, Nature Biotechnology, antimicrobial peptides Supports antimicrobial peptide mechanism section
  3. Proksch et al., 2014, Skin Pharmacology and Physiology, oral collagen peptides RCT Human RCT on collagen peptides and skin elasticity

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.